What Google Scholar research tells us about tirzepatide

The SURMOUNT trials: what the core published evidence shows

The most-cited tirzepatide papers on Google Scholar come from the SURMOUNT programme, published in the New England Journal of Medicine. SURMOUNT-1, which randomised 2,539 adults with obesity or overweight and at least one weight-related condition but without type 2 diabetes, reported average body-weight reductions of roughly 15% at 5mg, 19.5% at 10mg and around 20–21% at 15mg over 72 weeks. Those are averages, individual responses varied, and the trial required participants to follow a reduced-calorie diet and increase physical activity alongside treatment.

SURMOUNT-2 examined adults with both obesity and type 2 diabetes and found meaningful weight loss there too, though the absolute percentages were somewhat lower. SURMOUNT-5, published in 2025, is the head-to-head trial that generated the most Google Scholar traffic in that year: it compared tirzepatide against semaglutide 2.4mg directly over 72 weeks in 751 adults with obesity and no diabetes, and if you want a closer look at how those two medicines sit alongside each other, our page on Mounjaro or tirzepatide walks through the practical distinctions in more detail. NICE cited this evidence in its discussion notes when evaluating TA1026.

What the trials confirm is a consistent direction of effect across doses and populations. What they do not confirm (and what no published trial can tell you) is how a specific individual will respond. That is a clinical question, not a literature one.

Beyond weight loss: what else researchers are studying

A question our prescribers hear most weeks is whether tirzepatide has benefits beyond the number on the scale. The published literature does address this. SURMOUNT-OSA reported statistically significant improvements in obstructive sleep apnoea severity. Cardiovascular outcome data from the SURPASS-CVOT trial showed reductions in major cardiovascular events in adults with type 2 diabetes. Separate analyses have looked at blood pressure, triglycerides and liver-fat markers.

None of this is incidental. NICE's appraisal (TA1026, published in December 2024) considered the broader clinical picture, not just weight-loss data in isolation, when forming its recommendations. The dual GIP and GLP-1 mechanism is thought to contribute to metabolic effects beyond appetite suppression, which is one reason the research community has published so extensively on it. Google Scholar's citation counts for the major SURMOUNT papers now run into the thousands, which gives some sense of how quickly this has become a reference area in metabolic medicine.

For readers curious about how tirzepatide compares to other options in the evidence, the effectiveness question goes into that in more depth.

What the research means in a UK prescribing context

Published trials establish that tirzepatide works, at what doses and in what populations. They do not establish that it is right for any one person reading this page. UK prescribing sits within a regulated framework: tirzepatide (sold here as Mounjaro) is a prescription-only medicine, and a GPhC-registered Independent Prescriber decides suitability based on the individual's health history, current medicines and circumstances, not on the trial averages alone.

NICE TA1026 sets out NHS eligibility criteria, which centre on a BMI of 35 or above alongside at least one qualifying weight-related condition, with thresholds 2.5 kg/m² lower for certain ethnic backgrounds under UK guidance. Private prescription follows the licensed criteria in the medicine's SmPC: adults with a BMI of 30 or above, or 27 or above with a relevant weight-related condition, and our page covering tirzepatide l explores the licensed use and dosing structure in further detail. You can read more about how those criteria work in practice on the Mounjaro overview, or explore the broader weight-loss treatment options if you are still at the considering stage.

On cost: private treatment is priced per pen and varies by dose and provider. Since Eli Lilly raised UK list prices in September 2025, typical private market prices have ranged roughly £149–£375 per month. The Mounjaro pricing page sets out what those figures usually do and do not include. Treatment at this level is not a trivial spend, and understanding what clinical oversight is included in any quote matters as much as the headline number.

The evidence base on Google Scholar is genuinely useful for understanding tirzepatide's mechanism, its trial results and its place in metabolic medicine. Turning that into a safe, clinically appropriate prescription is a different step, and one that belongs with a qualified prescriber. Learn more about the team behind nume, or see common questions about how the service works before you decide.